Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression

Schmidt, G.; Meyberg-Solomayer, G; Gerlinger, Christoph; Juhasz‐Böss, I.; Herr, D.; Rody, Achim; Liedtke, Cornelia; Solomayer, Erich‐Franz

doi:10.1007/s00404-014-3331-4

Cited by 12 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 119 non-metastatic TNBCs, patients with a HER2-neu score of 0 had a significantly poorer outcome in terms of DFS and OS compared with those with a HER2 score of 1 or 2 ( P =0.0021, P =0.0105). 88 In our previous analysis of 47 patients with early-stage TNBC, we found the median EFS to be shorter in the HER2-positive, ISH-negative cases (29.2 months) than in the HER2-negative ones (31.8 months), without reaching significance ( P =0.9). 89 …”

Section: Discussionmentioning

confidence: 68%

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

Ilie¹,

Bacinschi²,

Botnariuc³

et al. 2018

BCTT

View full text Add to dashboard Cite

BackgroundTriple-negative breast cancer (TNBC) has a poor prognosis, even in its early stages. In the absence of postoperative targeted treatments, intensive adjuvant chemotherapy regimens are proposed. For those favorable histologies, such as apocrine and adenoid cystic carcinoma, which frequently belong to TNBC, aggressive treatments are unnecessary.Patients and methodsWe retrospectively analyzed 631 cases of breast cancer, primary operated curatively, and followed up at our institution for at least 36 months to identify the bio-markers assessable by immunohistochemistry, to be proposed as prognostic score for tailoring adjuvant treatment to TNBC patients.ResultsThe triple-negative phenotype was found in 85 patients (13.5%). Over a mean followup of 55.7 months, relapses occurred in 106 patients (16.8%), of which 18 (2.8%) were TNBC. Recurrence was directly correlated with Ki67 and cytokeratin 5/6 (CK5/6) immunoreactivity in all breast cancer patients (P=0.005), but only marginally with CK5/6 and epithelial cadherin (E-cad) expression in TNBC patients (P=0.07). Mean event-free survival (EFS) in TNBC patients was 85.52 months compared with 100.4 months in non-TNBC patients (P=0.228). The EFS of CK5/6-negative triple-negative patients was 68.84 months compared with 98.84 months in those who were CK5/6 positive (HR =5.08; P=0.038). EFS differed among patients identified as double-positive for E-cad and CK5/6 (83.87 months), those expressing E-cad or CK5/6 (64.23 months), and those negative for both biomarkers (39.64 months).ConclusionThese preliminary results suggest that CK5/6 and E-cad are possible core biomarkers for a cost-effective prognostic evaluation of primary operable TNBC patients.

show abstract

Section: Discussionmentioning

confidence: 68%

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

Ilie¹,

Bacinschi²,

Botnariuc³

et al. 2018

BCTT

View full text Add to dashboard Cite

show abstract

“…Some previous studies suggest that some known prognostic factors are not applicable for TNBC. For instance, Ki-67 and the grade did not show any prognostic value in TNBC according to a study by Schmidt et al (27). Rakha et al (28) finds that the patients' age, tumor size, and androgen receptor expression were not of significant value in determining the prognosis in a N0TNBC group.…”

Section: Discussionmentioning

confidence: 97%

“…And being younger is regarded as a classical poor prognostic factor that is related to loco-regional relapse, BCSS, and OS ( 24 ) with small breast cancer tumors ( 25 ). In addition, the histological grade of the tumor is also a recognized prognostic indicator connected with survival ( 26 , 27 ). Therefore, young age and high histological grade seem to be the usual reference factors when considering ACT for T1a TNBC patients.…”

Section: Discussionmentioning

confidence: 99%

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

Chen

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a subtype with distinct heterogeneity, high invasiveness, and poorer prognosis. There is a controversy about adjuvant chemotherapy (ACT) at the T1aN0M0 stage. This study was carried out to assess the survival benefit of ACT for these patients. Methods: We identified 1,099 patients with T1aN0M0 TNBC who were diagnosed between 2010 and 2016 from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariable analyses were conducted to determine factors related to survival. One-to-one (1:1) propensity score matching (PSM) was applied to construct a matched sample consisting of pairs of ACT and non-ACT subjects. Breast cancer-specific survival (BCSS) and overall survival (OS) of the two groups were evaluated by Kaplan-Meier plots and Cox proportional hazard regression models. Stratified analysis according to different variables was also performed. Results: No obvious differences in demographic or clinical characteristics were found between patients who had ACT and those without ACT therapy in terms of race, marital status, laterality, or radiation therapy. A higher proportion of patients who were older, had a higher histological grade tumor, and who received breast-conserving surgery had adjuvant chemotherapy. The ACT group did not exhibit better survival in BCSS or OS before PSM. After PSM, the ACT and non-ACT groups consisted of 255 patients, respectively, and Kaplan-Meier curves and multivariate analysis both indicate that adjuvant chemotherapy was not associated with better survival in terms of BCSS or OS. Furthermore, we did not observe any survival advantage in any subgroup irrespective of age, race, marital status, histological grade, surgery type, or radiotherapy status. Conclusions: The study results indicate that there is no strong association between ACT and better survival in T1aN0M0 TNBC. It implies that the chemotherapy decision should be made cautiously and further research into therapeutic strategies are needed in T1aN0M0 TNBC patients.

show abstract

An overview of triple-negative breast cancer

Kumar

Aggarwal

2015

Arch Gynecol Obstet

564

416

View full text Add to dashboard Cite

show abstract

Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression

Abstract: Besides tumour stage, grading and nodal status, the Her2-neu score 0 is able to function as a prognostic factor in patients with TNBC.

Cited by 12 publications

References 53 publications

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

An overview of triple-negative breast cancer

Contact Info

Product

Resources

About